General Information of Drug Transporter (DT)
DT ID DTD0009 Transporter Info
Gene Name SLC22A3
Transporter Name Organic cation transporter 3
Gene ID
6581
UniProt ID
O75751
Exogenous Factors (drugs, dietary constituents, etc.) Modulating DT Activity (EFMDA)
Exogenous Factor Quinine Approved Drug
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 22.7 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 18.3 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT3
DT Modulation Quinine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 37 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
DT Modulation Quinine inhibits the activity of SLC22A3 [4]
Exogenous Factor Tetraethylammonium Investigative Drug
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 1372 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human retinal pigment epithelial (HRPE) cells-OCT3
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1237 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT3
DT Modulation Tetraethylammonium inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 1476.6 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Clonidine Approved Drug
DT Modulation Clonidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 373 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human retinal pigment epithelial (HRPE) cells-OCT3
DT Modulation Clonidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 110 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Desipramine Approved Drug
DT Modulation Desipramine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 14 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human retinal pigment epithelial (HRPE) cells-OCT3
DT Modulation Desipramine inhibits the activity of SLC22A3 [7]
Exogenous Factor Metformin Approved Drug
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 904 microM) [6]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
DT Modulation Metformin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 2332 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT3
Exogenous Factor Ranitidine Approved Drug
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 372 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
DT Modulation Ranitidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 290 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT3
Exogenous Factor Estradiol Approved Drug
DT Modulation Estradiol inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 2.88 microM) [8]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Progesterone Approved Drug
DT Modulation Progesterone inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 4.28 microM) [8]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Phenoxybenzamine Approved Drug
DT Modulation Phenoxybenzamine inhibits the transportation of 1-Methyl-4-phenylpyridinium by SLC22A3 (IC50 = 6.13 microM) [8]
Affected Drug/Substrate 1-Methyl-4-phenylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Famotidine Approved Drug
DT Modulation Famotidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 6.7 microM) [2]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Oocytes-OCT3
Exogenous Factor Imipramine Approved Drug
DT Modulation Imipramine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 42 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human retinal pigment epithelial (HRPE) cells-OCT3
Exogenous Factor Procainamide Approved Drug
DT Modulation Procainamide inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 738 microM) [5]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human retinal pigment epithelial (HRPE) cells-OCT3
Exogenous Factor Prazosin Approved Drug
DT Modulation Prazosin inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 12.6 microM) [8]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor YM155 Drug in Phase 2 Trial
DT Modulation YM155 inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 108 microM) [9]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Phenformin Drug Withdrawn
DT Modulation Phenformin inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 134 microM) [6]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Ergotidine Approved Drug
DT Modulation Ergotidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 140 microM) [10]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Dizocilpine Discontinued Drug
DT Modulation Dizocilpine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 224 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Ketamine Approved Drug
DT Modulation Ketamine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 225.7 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Memantine Approved Drug
DT Modulation Memantine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 236 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Phencyclidine Investigative Drug
DT Modulation Phencyclidine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 333 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Dextroamphetamine Approved Drug
DT Modulation Dextroamphetamine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki = 460 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Amantadine Approved Drug
DT Modulation Amantadine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki > 1000 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Cocaine Approved Drug
DT Modulation Cocaine inhibits the transportation of N-methylpyridinium by SLC22A3 (Ki > 1000 microM) [11]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Human embryonic kidney 293 cells (HEK293)-OCT3
Exogenous Factor Pentamidine Approved Drug
DT Modulation Pentamidine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 14.8 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Antiparasitics Discontinued Drug
DT Modulation Antiparasitics inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 20.4 microM) [1]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Atropine Approved Drug
DT Modulation Atropine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 466 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Diphenhydramine Approved Drug
DT Modulation Diphenhydramine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 695 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
Exogenous Factor Etilefrine Drug Withdrawn
DT Modulation Etilefrine inhibits the transportation of N-methylpyridinium by SLC22A3 (IC50 = 4448 microM) [3]
Affected Drug/Substrate N-methylpyridinium Modulation Type Inhibition
Cell System Chinese hamster ovary (CHO) cells-OCT3
References
1 Transport of dicationic drugs pentamidine and furamidine by human organic cation transporters. Drug Metab Dispos. 2009 Feb;37(2):424-30.
2 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
3 Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60.
4 A new chemotype inhibitor for the human organic cation transporter 3 (hOCT3). Bioorg Med Chem Lett. 2017 Sep 15;27(18):4440-4445.
5 Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58.
6 Comparison of the kinetic characteristics of inhibitory effects exerted by biguanides and H2-blockers on human and rat organic cation transporter-mediated transport: Insight into the development of drug candidates. Xenobiotica. 2007 Jun;37(6):618-34.
7 Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3). J Psychiatr Res. 2008 Jul;42(8):605-11.
8 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
9 Characterization of human organic cation transporter 1 (OCT1/SLC22A1)- and OCT2 (SLC22A2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)- 4,9-dihydro-1H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos. 2010 Jan;38(1):1-4.
10 Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10.
11 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.